EUVIMEDEUVIMED entdecken
Übersichtsarbeit

COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy

Eleftheria Kampouri iD, Joshua A Hill, Veronica Dioverti iD

Transplant Infectious Disease · 2023

DOI: 10.1111/tid.14144 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transplant Infectious Disease, 2023. Verfasst von Eleftheria Kampouri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: COVID-19, Receptors, Chimeric Antigen, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 170 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

More than 3 years have passed since Coronavirus disease 2019 (COVID‐19) was declared a global pandemic, yet COVID‐19 still severely impacts immunocompromised individuals including those treated with hematopoietic cell transplantation (HCT) and chimeric antigen receptor‐T‐cell therapies who remain at high risk for severe COVID‐19 and mortality. Despite vaccination efforts, these patients have inadequate responses due to immunosuppression, which underscores the need for additional preventive approaches. The optimal timing, schedule of vaccination, and immunological correlates for protective immunity remain unknown. Antiviral therapies used early during disease can reduce mortality and severity due to COVID‐19. The combination or sequential use of antivirals could be beneficial to control replication and prevent the development of treatment‐related mutations in protracted COVID‐19. Despite conflicting data, COVID‐19 convalescent plasma remains an option in immunocompromised patients with mild‐to‐moderate disease to prevent progression. Protracted COVID‐19 has been increasingly recognized among these patients and has been implicated in intra‐host emergence of SARS‐CoV‐2 variants. Finally, novel SARS‐CoV2‐specific T‐cells and natural killer cell‐boosting (or ‐containing) products may be active against multiple variants and are promising therapies in immunocompromised patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Receptors, Chimeric AntigenHematopoietic Stem Cell TransplantationHumansSARS-CoV-2COVID-19 SerotherapyRNA, Viral

Stichwörter der Autor:innen

CAR-T-cell therapyCOVID-19SARS-CoV-2antiviralsconvalescent plasmahematopoietic cell transplantationvaccine

Substanzen

RNA, ViralReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Eleftheria Kampouri, Veronica Dioverti

Zitieren

APA

Kampouri, E., Hill, J. A., & Dioverti, V. (2023). COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy. Transplant Infectious Disease. https://doi.org/10.1111/tid.14144

Vancouver

Kampouri E, Hill JA, Dioverti V. COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy. Transplant Infectious Disease. 2023. doi:10.1111/tid.14144

BibTeX
@article{Kampouri2023,
  author = {Kampouri, Eleftheria and Hill, Joshua A and Dioverti, Veronica},
  title = {COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy},
  journal = {Transplant Infectious Disease},
  year = {2023},
  doi = {10.1111/tid.14144}
}
Kostenlos starten →